Multicentre Phase III Erythropoietic Protoporphyria Study

Inclusion Criteria: * Male or female patients with a diagnosis of EPP (confirmed by elevated free protoporphyrin in peripheral erythrocytes) of sufficient severity that they have requested treatment to alleviate their symptoms. * Aged 18-70 years. * Written informed consent prior to the performance of any study-specific procedure. Exclusion Criteria: * Any allergy to afamelanotide or the polymer contained in the implant or to lignocaine or other local anaesthetic used during the administration of study medication. * EPP patients with significant hepatic involvement. * Personal history of melanoma or dysplastic nevus syndrome. * Current Bowen's disease, basal cell carcinoma, squamous cell carcinoma, or other malignant or premalignant skin lesions. * Any other photodermatosis such as PLE, DLE or solar urticaria. * Diagnosed with HIV/AIDS or hepatitis. * Any evidence of clinically significant organ dysfunction or any clinically significant deviation from normal in the clinical or laboratory determinations. * Acute history of drug or alcohol abuse (in the last 12 months). * History of disorders of the gastrointestinal, hepatic, renal, cardiovascular, respiratory, endocrine (including diabetes, Cushing's syndrome, Addison's disease, Peutz-Jeagher syndrome), neurological (including seizures), haematological (especially anaemia of less than 10 g/100 mL) or systemic disease judged to be clinically significant by the Investigator. * Major medical or psychiatric illness * Patient as…